Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The main objective is to show that the addition of Galvus versus placebo in patients with
type 2 diabetes treated with metformin (at the maximum tolerated dose) and basal insulin
properly titrated, allows a greater proportion of patients achieving an HbA1c below 7%.
The primary efficacy endpoint was the percentage of patients responding to treatment (HbA1c
less than 7%) after 3 months of treatment with Galvus or placebo
Phase:
Phase 4
Details
Lead Sponsor:
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète